New injection for ulcerative colitis enters early human testing
NCT ID NCT06681389
First seen May 09, 2026
Summary
This early-stage trial tested a new drug called NP-201 acetate in 35 healthy volunteers and people with mild-to-moderate ulcerative colitis. The drug is given as an injection under the skin. The main goals were to check safety, how the body processes the drug, and the right dose. This is a first step to see if NP-201 acetate might help control ulcerative colitis in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NP-201 acetate injection
What this could lead to
If this early study shows promise, NP-201 acetate could become a new treatment option for people with mild-to-moderate ulcerative colitis.
What could go wrong
This is a very early Phase 1b/2a trial with only 35 participants, focused on safety and dosing. It is too small to prove effectiveness, and many early-stage drugs fail to show benefit in larger trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.